Skip to the answer

Oliceridine Injection

Oliceridine Injection (Olinvyk) is an intravenous opioid pain medicine for adults with acute pain severe enough to need an IV opioid when other treatments aren't enough.

Brand name Olinvyk
Rx Schedule CII Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Oliceridine Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Olinvyk (oliceridine) is a strong IV opioid that acts on mu-opioid receptors, the brain’s pain-control docking sites, given in hospital to adults whose acute pain needs an IV opioid when other treatments fall short; on the market since about 2020, it is less familiar than standbys like morphine. It is tolerated like other opioids; most people notice nausea, vomiting, dizziness, drowsiness or itching. Its boxed warning covers life-threatening slowed breathing, addiction and dangerous sedation with benzodiazepines, other sedatives or alcohol, so speak up right away about trouble breathing or extreme sleepiness. Tell your care team every medicine you take; some antidepressants and antibiotics can raise its levels and stretch out its effects.

Clinical pearls

  • With a patient-controlled pump, only the patient should press the button, never a family member trying to help.
  • Mention any buprenorphine, nalbuphine or butorphanol use, since these can blunt its pain relief or trigger withdrawal.
  • It has a firm daily dose ceiling because larger totals may disturb heart rhythm (QTc prolongation, a change seen on an ECG).
  • Gabapentin and pregabalin, often added after surgery, deepen its sedation and slowed breathing much as benzodiazepines do.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Olinvyk can cause life-threatening slowed breathing, addiction and overdose. These are the main risks the FDA highlights.

  • Addiction, abuse and misuse: These can happen even at recommended doses and can lead to overdose and death. Your risk will be assessed and checked again over time.
  • Slowed breathing: This can be fatal and is most likely when starting or after a dose increase, so careful dosing is essential.
  • Mixing with sedatives: Taking it with benzodiazepines, other sedating drugs or alcohol can cause profound sleepiness, slowed breathing, coma and death. This combination is used only when no other options work.
  • Pregnancy: Using opioids for a long time during pregnancy can cause life-threatening withdrawal in the newborn. Neonatal specialists should be available at delivery.
Read the full warning on DailyMed →
How you get itPrescription only
Comes asInjection
Earliest FDA record2020
Companies listing it with the FDA1
FDA label last updatedDec 31, 2025
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Oliceridine Injection, written from its FDA label.

What Oliceridine Injection is used for

▾

Oliceridine Injection is used for one main purpose.

  • Olinvyk (intravenous) is used in adults for acute pain severe enough to require an IV opioid pain medicine, when other treatments are inadequate.
  • It is reserved for patients whose other options are ineffective, not tolerated, or not enough to manage the pain.

How Oliceridine Injection works

▾

Oliceridine is a full opioid agonist that mainly targets the mu-opioid receptor. These receptors sit throughout the brain and spinal cord and are thought to play a role in how the body senses pain.

Like other full opioids, there is no ceiling to its pain-relieving effect. In practice, the dose is limited by side effects such as slowed breathing and sedation.

Oliceridine Injection dosage

▾

Olinvyk is given only through a vein, either by a healthcare provider or by a patient-controlled pump. With the pump, you press a button for small doses, and a lock-out period prevents doses from being too close together.

  • The lowest effective dose is used for the shortest time.
  • Your care team adjusts the dose based on your pain and side effects.
  • There is a daily maximum, and it has not been studied in controlled trials beyond 48 hours.
  • If it has been used regularly, it is tapered down gradually rather than stopped suddenly.

Dosing details from the FDA-approved label

From the Oliceridine Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Initial dose (acute pain, intravenous administration by healthcare provider)
    • Initiate treatment with a 1.5 mg dose
    • Maximum: Single doses greater than 3 mg not to be administered; cumulative total daily dose should not exceed 27 mg
    • Use beyond 48 hours not studied in controlled clinical trials
  • Patient controlled analgesia (PCA)
    • Initial dose can be followed by patient demand doses of 0.35 mg with a 6-minute lock-out
    • A demand dose of 0.5 mg may be considered for some patients if the potential benefit outweighs the risks
    • Maximum: Cumulative total daily dose should not exceed 27 mg
    • 30 mg/30 mL (1 mg/mL) vial is for PCA use only; draw directly without diluting
  • Supplemental doses
    • 0.75 mg administered by healthcare providers, beginning 1 hour after the initial dose, and hourly thereafter as needed
    • Maximum: Single doses greater than 3 mg not to be administered; cumulative total daily dose should not exceed 27 mg
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION For intravenous administration only. OLINVYK should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. ( 2.1 ) Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Reserve titration to higher doses of OLINVYK for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. ( 2.1 , 5 ) Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse and misuse. ( 2.1 , 5.1 ) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with OLINVYK. Consider this risk when selecting an initial dose and when making dose adjustments. ( 2.1 , 5.2 ) Initiate treatment with a 1.5 mg dose. ( 2.2 ) For patient controlled analgesia (PCA), recommended demand dose is 0.35 mg, with a 6-minute lock-out. A demand dose of 0.5 mg may be considered. ( 2.2 ) Supplemental doses of 0.75 mg can be administered, beginning 1 hour after the initial dose, and hourly thereafter, as needed. ( 2.2 ) Periodically reassess patients receiving OLINVYK to evaluate the continued need for opioid analgesics to maintain pain control, for the signs or symptoms of adverse reactions, and for the development of addiction, abuse, or misuse. ( 2.3 ) Do not rapidly reduce or abruptly discontinue OLINVYK in a physically-dependent patient. ( 2.4 , 5.14 ) 2.1 Important Dosage and Administration Instructions For intravenous administration only. OLINVYK should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. Individual single doses greater than 3 mg have not been evaluated. The cumulative daily dose should not exceed 27 mg. OLINVYK 30 mg/30 mL (1mg/mL) vial is intended for patient-controlled analgesia (PCA) use only. Draw OLINVYK directly from the vial into the PCA syringe or IV bag without diluting. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions ( 5 )] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Oliceridine Injection side effects

▾

The most common side effects seen in clinical trials were:

Common side effects

  • Nausea
  • Vomiting
  • Dizziness
  • Headache
  • Constipation
  • Itching
  • Low oxygen levels (hypoxia)
  • Drowsiness or sedation

When to get medical help

  • Slow, shallow or troubled breathing, extreme sleepiness or trouble waking up. These can be life-threatening and are most likely when starting or after a dose increase.
  • Signs of overdose: pinpoint pupils, cold clammy skin, limp muscles, very slow heartbeat or fainting.
  • Severe dizziness, lightheadedness or fainting from very low blood pressure.
  • Signs of serotonin syndrome if you take other serotonin-affecting drugs.
  • Pain that gets worse or becomes more sensitive after the dose goes up (opioid-induced hyperalgesia).
  • Signs of adrenal insufficiency: nausea, vomiting, loss of appetite, tiredness, weakness, dizziness, low blood pressure.
  • Allergic reaction, such as hives or anaphylaxis.
  • Cravings, misuse or withdrawal symptoms if the medicine is stopped suddenly after regular use.

Oliceridine Injection warnings and precautions

▾
  • Slowed breathing can be life-threatening, especially when starting or after a dose increase. Older, frail or debilitated people and those with chronic lung disease are at higher risk.
  • Addiction, abuse and misuse can occur even at recommended doses.
  • Sedatives and alcohol combined with it can cause coma and death.
  • Heart rhythm: Daily totals above 27 mg may increase the risk of QTc prolongation.
  • Low blood pressure and fainting can occur, especially with low blood volume or circulatory shock.
  • Head injury, brain tumor or raised pressure in the head: it can increase sedation and breathing problems.
  • Adrenal insufficiency, opioid-induced hyperalgesia and withdrawal have been reported with opioids.

Oliceridine Injection interactions

▾

Several types of medicines can change how Olinvyk works or add to its risks.

  • Benzodiazepines, alcohol and other sedating drugs: profound sedation and slowed breathing.
  • CYP2D6 and CYP3A4 inhibitors (such as paroxetine, fluoxetine, erythromycin, ketoconazole, ritonavir): raise oliceridine levels and prolong effects.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin): lower levels and may weaken pain relief or cause withdrawal.
  • Serotonergic drugs: risk of serotonin syndrome.
  • Buprenorphine, butorphanol, nalbuphine, pentazocine: may reduce pain relief or trigger withdrawal.
  • Muscle relaxants: may increase breathing depression.
  • Anticholinergics: may increase urinary retention and severe constipation.
  • Diuretics: opioids may reduce their effect.

Interactions listed in the FDA-approved label

From the Oliceridine Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Moderate to strong inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, quinidine, bupropion): Can increase the plasma concentration of oliceridine, resulting in increased or prolonged opioid effects. May require less frequent dosing; monitor closely for respiratory depression and sedation and base subsequent doses on severity of pain and response. If the inhibitor is discontinued, increase of the OLINVYK dosage may be considered until stable drug effects are achieved; monitor for signs of opioid withdrawal.
  • Moderate to strong inhibitors of CYP3A4 (e.g., erythromycin, ketoconazole, ritonavir): Can increase the plasma concentration of oliceridine, resulting in increased or prolonged opioid adverse reactions; after the inhibitor is stopped, oliceridine concentration may decrease, resulting in decreased efficacy or withdrawal syndrome in physically dependent patients. Use caution; patients may require less frequent dosing; monitor for respiratory depression and sedation at frequent intervals. If the inhibitor is discontinued, increase of dosage may be considered until stable drug effects are achieved; monitor for signs of opioid withdrawal.
  • Strong and moderate CYP3A4 inhibitors together with CYP2D6 inhibitors: Inhibition of both pathways can result in a greater increase of oliceridine plasma concentrations and prolong opioid adverse reactions. Patients may require less frequent dosing; monitor closely for respiratory depression and sedation at frequent intervals, and base subsequent doses on severity of pain and response to treatment.
  • Inducers of CYP3A4 (rifampin, carbamazepine, phenytoin): Can decrease oliceridine plasma concentration, resulting in decreased efficacy or withdrawal syndrome in physically dependent patients; after stopping the inducer, concentration may increase and may cause serious respiratory depression. If concomitant use is necessary, increase of dosage may be considered until stable drug effects are achieved and monitor for opioid withdrawal. If the inducer is discontinued, consider dosage reduction and monitor for respiratory depression.
  • Benzodiazepines and other CNS depressants (including alcohol): Due to additive pharmacologic effect, increases the risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing for patients for whom alternative options are inadequate; limit dosages and durations to the minimum required; monitor closely for respiratory depression and sedation.
  • Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, MAO inhibitors, etc.): Concomitant use of opioids with drugs affecting the serotonergic system has resulted in serotonin syndrome. If concomitant use is warranted, observe the patient carefully, particularly during treatment initiation and dose adjustment; discontinue OLINVYK if serotonin syndrome is suspected.
  • Mixed agonist/antagonist and partial agonist opioid analgesics (butorphanol, nalbuphine, pentazocine, buprenorphine): May reduce the analgesic effect of OLINVYK and/or precipitate withdrawal symptoms. Avoid concomitant use.
  • Muscle relaxants: OLINVYK may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Monitor for signs of respiratory depression and decrease the dosage of OLINVYK and/or the muscle relaxant as necessary.
  • Diuretics: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor for signs of diminished diuresis and/or effects on blood pressure and increase the diuretic dosage as needed.
  • Anticholinergic drugs: May increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with OLINVYK. Table 6: Clinically Significant Drug Interactions with OLINVYK Moderate to Strong Inhibitors of CYP2D6 Clinical Impact: Concomitant administration of a moderate to strong CYP2D6 inhibitor can increase the plasma concentration of oliceridine [see Clinical Pharmacology ( 12.3 )] , resulting in increased or prolonged opioid effects. Intervention: If concomitant use is necessary, patients taking a moderate to strong CYP2D6 inhibitor may require less frequent dosing of OLINVYK. Monitor closely for respiratory depression and sedation at frequent intervals and base subsequent doses on the patient’s severity of pain and response to treatment. If a CYP2D6 inhibitor is discontinued, increase of the OLINVYK dosage may be considered until stable drug effects are achieved. Monitor for signs of opioid withdrawal. Examples: Paroxetine, fluoxetine, quinidine, bupropion Moderate to Strong Inhibitors of CYP3A4 Clinical Impact: The concomitant administration of moderate to strong CYP3A4 inhibitors can increase the plasma concentration of oliceridine, resulting in increased or prolonged opioid adverse reactions. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oliceridine concentration may decrease, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oliceridine [see Warnings and Precautions ( 5.14 )] . Intervention: Caution should be used when administering OLINVYK to patients taking inhibitors of the CYP3A4 enzyme. If concomitant use is necessary, patients taking a CYP3A4 inhibitor may require less frequent dosing. Monitor patients for respiratory depression and sedation at frequent intervals. If a CYP3A4 inhibitor is discontinued, increase of the OLINVYK dosage may be considered until stable drug effects are achieved. Monitor for signs of opioid withdrawal.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿158 supplements and herbs with documented Oliceridine Injection interactions, ranked by severity Check Oliceridine Injection against a supplement or herb →

Before taking Oliceridine Injection

▾
  • Not for people with significant respiratory depression, acute or severe asthma in an unmonitored setting, a known or suspected bowel blockage, or an allergy to oliceridine.
  • Tell your care team about any personal or family history of substance misuse or mental illness.
  • Caution with COPD, other lung problems, head injury, brain tumor or circulatory shock.
  • Pregnancy: it can cause newborn withdrawal with long-term use and is not recommended around labor.
  • Breastfeeding: infants should be watched for sleepiness and slowed breathing.
  • Not established for children.
  • Older adults may be more sensitive and are dosed cautiously.
  • Severe liver impairment may call for a lower starting dose. Kidney impairment does not require dose adjustment.

Oliceridine Injection overdose

▾

Overdose can cause slowed breathing, extreme sleepiness progressing to stupor or coma, limp muscles, cold clammy skin, small pupils, slow heartbeat and low blood pressure. It can be fatal. Treatment focuses on keeping the airway open and supporting breathing, and giving a reversal agent such as naloxone or nalmefene, with close monitoring because reversal may wear off sooner than oliceridine.

What Oliceridine Injection does in the body

▾

Oliceridine produces pain relief, and in animal models this effect can be blocked by naloxone. Like other opioids, it reduces the brain's drive to breathe, slows the gut (causing constipation), causes pinpoint pupils, and widens blood vessels, which can lower blood pressure. In a study after bunionectomy, pain relief began within about 1 to 3 minutes of the first dose. It also causes a mild, dose-related lengthening of the QTc interval on heart tracings.

How your body processes Oliceridine Injection

▾

Oliceridine spreads widely into body tissues, and the unchanged drug has a half-life of roughly 1.3 to 3 hours. The liver breaks it down mainly through the CYP3A4 and CYP2D6 enzymes into inactive byproducts. Most of these are passed in the urine, with the rest in stool, and very little unchanged drug leaves in the urine. Liver disease can lengthen its half-life, while kidney disease did not significantly change clearance.

How to store Oliceridine Injection

▾

Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) . Protect from freezing. Protect from light.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

158

Supplements & herbs that interact with Oliceridine Injection

158 supplements and herbal products have documented interactions with Oliceridine Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 118
  • Minor · 32
AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major LITHIUM Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major +150 more
Every supplement checked against Oliceridine Injection — ranked by severity The full interaction hub: 8 major · 118 moderate · 32 minor · every one linked to its full report. Check Oliceridine Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Oliceridine Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Oliceridine Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is Olinvyk used for?

▾
It's an IV opioid given to adults for acute pain that is severe enough to need an intravenous opioid, when other treatments aren't enough. It's meant for those situations, not for pain that other options can manage.

How will I receive it?

▾
Only through a vein. A nurse or other healthcare provider may give the doses, or you may use a pump where you press a button for small doses, with a built-in waiting period between them. Your care team picks the dose and checks on you regularly.

What side effects should I expect?

▾
The most common are nausea, vomiting, dizziness, headache, constipation, itching and low oxygen levels. Let your nurse know if any of these bother you. Tell them right away if you feel extremely sleepy or have trouble breathing.

Can I drink alcohol or take sleep or anxiety medicines with it?

▾
Please don't unless your care team has approved it. Alcohol, benzodiazepines and other sedating medicines can combine with opioids to cause profound sleepiness, slowed breathing, coma and death. Give us a full list of everything you take.

Can I become addicted to it?

▾
Addiction can happen with any opioid, even when it's used as prescribed, and the risk grows with higher doses. Your risk will be considered and reviewed, so be open about any past substance use or mental health history.

Is it safe in pregnancy or while breastfeeding?

▾
Using opioids for a long time during pregnancy can cause withdrawal in the newborn, and Olinvyk is not recommended around labor. It isn't known whether it passes into breast milk, so babies should be watched for sleepiness and slow breathing. Talk with your prescriber about your situation.

Is Oliceridine Injection available over the counter?

▾
No. Oliceridine Injection is a prescription medicine: every Oliceridine Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is Oliceridine Injection a controlled substance?

▾
Yes — Oliceridine Injection is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was Oliceridine Injection first available?

▾
The earliest FDA record we hold for Oliceridine Injection is from 2020: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Oliceridine Injection was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Oliceridine Injection on HelloPharmacist

📊Oliceridine Injection supplement interactions158 checked — ranked by severity 🌿Drug & Supplement CheckerOliceridine Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Oliceridine Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Oliceridine Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Oliceridine Injection forms and strengths (how it comes)

Oliceridine Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Into a vein
Brands Olinvyk
How this form is used
What it may be used for
  • Olinvyk is used in adults for acute pain severe enough to require an intravenous opioid when alternative treatments are inadequate.
Important instructions
  • Olinvyk is for intravenous use only.
  • Olinvyk can be given by a healthcare provider or through patient-controlled analgesia (PCA) with a built-in lock-out between demand doses.
  • The Olinvyk 30 mg/30 mL vial is intended for PCA use only.
  • Olinvyk should be a clear, colorless solution, and it is not used if it looks cloudy or contains particles.
Available strengths 3 strengths
1 mg/mL 2 mg/2 mL 20 kg/20 kg
7 FDA-listed product records ⓘ

Oliceridine Injection on the U.S. market: products, makers and brands

How Oliceridine Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Oliceridine Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2020. Brand names on the directory include Olinvyk; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
2
FDA-listed product records ⓘ
2020
Earliest FDA record ⓘ

Compare Oliceridine Injection products

A representative set of FDA-listed product records for Oliceridine Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
1 mg/mL Intravenous Trevena, Inc. NDA View NDC →
2 mg/2 mL Intravenous Trevena, Inc. NDA View NDC →

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Oliceridine Injection NDCs →

Oliceridine Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Oliceridine recalls since July 2021.

✅No Oliceridine recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Oliceridine Injection RxCUI 2392230 1 dose form · 3 strengths

Look up RxCUI 2392230 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Oliceridine Injection brand names

Oliceridine Injection is sold under one brand name in the FDA directory — Olinvyk. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Olinvyk

Who makes Oliceridine Injection: manufacturers and labelers

One company lists Oliceridine Injection products with the FDA. By number of product records, the largest are Trevena, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Trevena, Inc. 2

Oliceridine Injection drug class (RxNorm)

Oliceridine Injection belongs to the Other opioids class.

Drug family (ATC) Other opioids

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Oliceridine Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Dec 31, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Oliceridine Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Oliceridine Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
2
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Trevena, Inc.
Linked label effective
Dec 31, 2025
Composite sections available
24
Linked SPL Set ID
ce167984-8b9d-40b7-84ce-d0f33fff1eaa
Linked SPL Document ID
43ecba1a-fa95-40e0-a383-8f9cdb6ad6b6
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Trevena, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →